Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Couples presenting to the infertility clinic- Do they really have infertility...
Angiogenesis Viena 2010
1. Angiogenesis A key factor in Shockwave Medicine Prof Dr Carlos Leal MD Bosque University & Fenway Medical – Bogota, Colombia Prof Dr. Manuel Brañes Chile University – Santiago de Chile
5. Musculoskeletal Shockwave Therapy Joint Meeting of the Austrian, Swiss, and German Societies for Orthopaedic ESWT DIGEST Deutsche und internationale Gesellschaft für extrakorporale Stoßwellentherapie Venue University Hospital Lecture Hall, Building 505 Langenbeckstr. 1 D-55101 Mainz Germany Orthopaedic Hospital Kassel Dept. of Orthopaedics Preliminary Programme March 30 – 31, 2001
6. Scientific Organization: Dr. Jan D. Rompe, MD, Associate Professor Dept. of Orthopaedics, Johannes Gutenberg University, Mainz Prof. Werner Siebert, MD, Chief Orthopaedic Hospital, Kassel Prof. Jochen Heine, MD, Chief Dept. of Orthopaedics, Johannes Gutenberg University, Mainz General Information: Dr. Carsten Schoellner, MD Mrs. Doris Becker Tel. 0049-06131-172748 Fax: 0049-06131-176679 e-mail: [email_address] Web: http://www.uni-mainz.de/FB/Medizin/Orthopaedie/ESWT.htm Dept. of Orthopaedics, Johannes Gutenberg University School of Medicine, Langenbeckstr. 1, D-55101 Mainz, Germany Dear colleagues, for ten years extracorporeal shockwaves have been used in clinical and experimental studies at the Department of Or-thopaedics of the Johannes Gutenberg University School of Medicine in Mainz, Germany. During the past decade various working groups have been founded in Austria, Switzerland, and Germany to concen-trate national and international efforts on training, quality management, basic research and organization of multi-center studies. For the first time the five leading national and international societies come together to exchange their vast experience with regard to ESWT in Orthopaedics. So there will be a unique opportunity to be informed about the present role of ESWT in comparison with generally recognized conservative or operative procedures. This is particularly interesting as one shockwave device recently received FDA approval for treatment of heel pain We would like to welcome you here in Mainz, Germany, to learn with us about chances and limits of this new tech-nology. Yours sincerly, Jan-Dirk Rompe Werner Siebert Jochen Heine Welcome 11.00 - 12.00 am Future Developments Chairmen: H. Kuderna, Wien, U. Dreisilker, Velbert Storz Medical - Direx – HMT - Dornier - EMS - Exogen - Shock Waves Inc. - MTS - Wolf - Siemens 12.00 - 1.00 pm Experimental Forum Chairmen: S. Wanke, Wiener Neustadt, P. Eysel, Mainz M. Maier, T. Saisu, C. Schmitz, S. Milz, J. Beckmann and H.J. Refior, Munich A. Thon, M. Bette and M. Haake, Marburg K. Peers, P. Brys, R. Lysens, Leuven, Belgium L. Gerdesmeyr, E. Steinhauser and W. Mittelmeier, Munich T. Rosendahl, P. Eysel and J.-D. Rompe, Mainz C. Leal, Bosque University, Bogota Colombia 1.30 - 3.00 pm ESWT for Calcifying Tendinitis Chairmen: J. Zoellner, Mainz, W. Siebert, Kassel S. Rupp, Homburg M. Daecke and M. Loew, Heidelberg M. Haake, and P. Griss, Marburg B. Dubs, Zürich R. Rädel, Herne H. Durst, St. Gallen 3.15 – 5.15 pm ESWT for Tennis Elbow Chairmen: B. Dubs, Zürich, R. Thiele, Berlin J. Fritze, Cologne L. Gerdesmeyr, R. Garve, K. Bachfischer and R. Gradinger, Munich C. Riedel, J.-D. Rompe and J. Heine, Mainz M. Haake and I. Boeddeker, Marburg D. Steeger v. Keitz, Rüsselsheim M. Maier, C. Schmitz, M. Steinborn, A. Stäbler and H.J. Refior, Munich G. Haupt, Cologne J. Haist, Wörrstadt 5.30 - 7.00 pm Advances in Musculoskeletal ESWT Chairmen:L. Gerdesmeyr, Munich, M. Haake, Marburg R. Thiele, Berlin, Germany S.P. Jacobs, Markham, Canada S. Lauber, J. Ludwig and J. Krämer, Kassel/Bochum, Germany M.Berta, L. Berta and R. Frairia, Torino, Italy S. McClure, McCarroll, D. VanSickle, West Lafayette, USA S. Donati, L. Fusetti, R. Ferrario, M. Berta, and R. Frairia, Torino, Italy S. Wanke, Wiener Neustadt, W. Schaden Austria Programme Friday, 30th March 2001 1.00 - 2.00 pm Registration 2.00 - 2.15 pm Welcome J. Heine, Mainz W. Siebert, Kassel, C. Schöllner, Mainz 2.15 - 2.45 pm Presentation of the Societies Chairmen: L. Gerdesmeyr, Munich, V. Auersperg, Linz Working Group of the ÖGO - Swiss Society for Shockwave Therapy (SGST) – German and International Society for Shockwave Therapy (DIGEST) - ISMST - Working Group ESWT of the DGOT 2.45 - 3.30 pm Guest Lectures Chairmen: P. Galle, Mainz, G. Haupt, Cologne S. Melchior and J.W. Thüroff, Mainz M. Sackmann, München 4.00 - 4.45 pm Basics Chairmen: M. Buch, Kassel, M. Haake, Marburg R. Prümmer, Karlsruhe O. Wess, Kreuzlingen 5.00 – 6.30 pm ESWT for Non-Unions Chairmen: P.M. Rommens, Mainz, R. Rädel, Herne P. Eysel, Mainz W. Schaden and H. Kuderna, Wien R. Wirsching, W. Eich, and P. Lang, Regensburg V. Auersperg and N. Böhler, Linz R. Diesch, Friedrichshafen H.-C. Pape and H. Tscherne, Hannover H.W. Ditzen and M. Börner, Frankfurt Saturday, 31st March 2001 9.00 - 10.45 am ESWT for Plantar Fasciitis Chairmen: J. Heine, Mainz, M. Maier, Munich H.-H. Küster, Gütersloh M. Buch and W. Siebert, Kassel L.S. Weil,Vernon Hills, USA R. Seil, S. Rupp and D.M. Kohn, Homburg L. Perlick and J. Grifka, Regensburg U. Dreisilker, Velbert C. Schoellner, T. Walz and J. Heine, Mainz J. Ogden, R. Alvarez, and R. Levitt, Atlanta, USA OWC
7. Scientific Organization: Dr. Jan D. Rompe, MD, Associate Professor Dept. of Orthopaedics, Johannes Gutenberg University, Mainz Prof. Werner Siebert, MD, Chief Orthopaedic Hospital, Kassel Prof. Jochen Heine, MD, Chief Dept. of Orthopaedics, Johannes Gutenberg University, Mainz General Information: Dr. Carsten Schoellner, MD Mrs. Doris Becker Tel. 0049-06131-172748 Fax: 0049-06131-176679 e-mail: [email_address] Web: http://www.uni-mainz.de/FB/Medizin/Orthopaedie/ESWT.htm Dept. of Orthopaedics, Johannes Gutenberg University School of Medicine, Langenbeckstr. 1, D-55101 Mainz, Germany Dear colleagues, for ten years extracorporeal shockwaves have been used in clinical and experimental studies at the Department of Or-thopaedics of the Johannes Gutenberg University School of Medicine in Mainz, Germany. During the past decade various working groups have been founded in Austria, Switzerland, and Germany to concen-trate national and international efforts on training, quality management, basic research and organization of multi-center studies. For the first time the five leading national and international societies come together to exchange their vast experience with regard to ESWT in Orthopaedics. So there will be a unique opportunity to be informed about the present role of ESWT in comparison with generally recognized conservative or operative procedures. This is particularly interesting as one shockwave device recently received FDA approval for treatment of heel pain We would like to welcome you here in Mainz, Germany, to learn with us about chances and limits of this new tech-nology. Yours sincerly, Jan-Dirk Rompe Werner Siebert Jochen Heine Welcome 11.00 - 12.00 am Future Developments Chairmen: H. Kuderna, Wien, U. Dreisilker, Velbert Storz Medical - Direx – HMT - Dornier - EMS - Exogen - Shock Waves Inc. - MTS - Wolf - Siemens 12.00 - 1.00 pm Experimental Forum Chairmen: S. Wanke, Wiener Neustadt, P. Eysel, Mainz M. Maier, T. Saisu, C. Schmitz, S. Milz, J. Beckmann and H.J. Refior, Munich A. Thon, M. Bette and M. Haake, Marburg K. Peers, P. Brys, R. Lysens, Leuven, Belgium L. Gerdesmeyr, E. Steinhauser and W. Mittelmeier, Munich T. Rosendahl, P. Eysel and J.-D. Rompe, Mainz C. Leal, Bosque University, Bogota Colombia 1.30 - 3.00 pm ESWT for Calcifying Tendinitis Chairmen: J. Zoellner, Mainz, W. Siebert, Kassel S. Rupp, Homburg M. Daecke and M. Loew, Heidelberg M. Haake, and P. Griss, Marburg B. Dubs, Zürich R. Rädel, Herne H. Durst, St. Gallen 3.15 – 5.15 pm ESWT for Tennis Elbow Chairmen: B. Dubs, Zürich, R. Thiele, Berlin J. Fritze, Cologne L. Gerdesmeyr, R. Garve, K. Bachfischer and R. Gradinger, Munich C. Riedel, J.-D. Rompe and J. Heine, Mainz M. Haake and I. Boeddeker, Marburg D. Steeger v. Keitz, Rüsselsheim M. Maier, C. Schmitz, M. Steinborn, A. Stäbler and H.J. Refior, Munich G. Haupt, Cologne J. Haist, Wörrstadt 5.30 - 7.00 pm Advances in Musculoskeletal ESWT Chairmen:L. Gerdesmeyr, Munich, M. Haake, Marburg R. Thiele, Berlin, Germany S.P. Jacobs, Markham, Canada S. Lauber, J. Ludwig and J. Krämer, Kassel/Bochum, Germany M.Berta, L. Berta and R. Frairia, Torino, Italy S. McClure, McCarroll, D. VanSickle, West Lafayette, USA S. Donati, L. Fusetti, R. Ferrario, M. Berta, and R. Frairia, Torino, Italy S. Wanke, Wiener Neustadt, W. Schaden Austria Programme Friday, 30th March 2001 1.00 - 2.00 pm Registration 2.00 - 2.15 pm Welcome J. Heine, Mainz W. Siebert, Kassel, C. Schöllner, Mainz 2.15 - 2.45 pm Presentation of the Societies Chairmen: L. Gerdesmeyr, Munich, V. Auersperg, Linz Working Group of the ÖGO - Swiss Society for Shockwave Therapy (SGST) – German and International Society for Shockwave Therapy (DIGEST) - ISMST - Working Group ESWT of the DGOT 2.45 - 3.30 pm Guest Lectures Chairmen: P. Galle, Mainz, G. Haupt, Cologne S. Melchior and J.W. Thüroff, Mainz M. Sackmann, München 4.00 - 4.45 pm Basics Chairmen: M. Buch, Kassel, M. Haake, Marburg R. Prümmer, Karlsruhe O. Wess, Kreuzlingen 5.00 – 6.30 pm ESWT for Non-Unions Chairmen: P.M. Rommens, Mainz, R. Rädel, Herne P. Eysel, Mainz W. Schaden and H. Kuderna, Wien R. Wirsching, W. Eich, and P. Lang, Regensburg V. Auersperg and N. Böhler, Linz R. Diesch, Friedrichshafen H.-C. Pape and H. Tscherne, Hannover H.W. Ditzen and M. Börner, Frankfurt Saturday, 31st March 2001 9.00 - 10.45 am ESWT for Plantar Fasciitis Chairmen: J. Heine, Mainz, M. Maier, Munich H.-H. Küster, Gütersloh M. Buch and W. Siebert, Kassel L.S. Weil,Vernon Hills, USA R. Seil, S. Rupp and D.M. Kohn, Homburg L. Perlick and J. Grifka, Regensburg U. Dreisilker, Velbert C. Schoellner, T. Walz and J. Heine, Mainz J. Ogden, R. Alvarez, and R. Levitt, Atlanta, USA
8. ONLAT Sociedad Latinoamericana de Litotripcia Ortopedica por Ondas de Choque Sociedade Latinoamericana de Terapia por Ondas de Choque Latin American Society for Musculoskeletal Shockwave Therapy
10. ONLAT Sociedad Latinoamericana de Litotripcia Ortopedica por Ondas de Choque Latin American Society for Musculoskeletal Shockwave Therapy
11.
12.
13. Wound healing is a complex and sequential local cellular and molecular response It overlaps biological processes generally defined by… Inflammation Epithelialization Angiogenesis Matrix deposition
14. During early wound healing, a vigorous angiogenic response supports the increased metabolic demands of rapidly proliferating and migrating leukocytes, keratinocytes, fibroblasts, and endothelial cell (EC) precursors
15. These early angiogenic and inflammatory responses diminish as wound closure, fibrosis, and remodeling predominate
16. The inability to progress through the inflammatory phase of healing is characteristic of chronic lesions
17. Prolonged and aberrant accumulation of matrix metalloproteinases (MMPs) Impedes cell migration and downregulation of tissue inhibitors of MMPs, hinders neovascularization essential to restoration of local O2 delivery, and interferes with extra-cellular matrix (ECM) remodeling
18. Various therapeutic strategies have been proposed to accelerate epidermal cell proliferation and angiogenesis within the open wound bed however, attempts to use soluble mediators and growth factors have been unfulfilling
19.
20.
21.
22. Recent studies have emphasized the importance of the wound stimulatory effects of micromechanical forces (‘‘cellular mechanotransduction’’) Ingber DE (2006) Cellular mechanotransduction: putting all the pieces together again. FASEB J 20:811 Pietramaggiori G, Liu P, Scherer SS, Kaipainen A, (2007) Tensile forces stimulate vascular remodeling and epidermal cell proliferation in living skin. Ann Surg 246:896
23. One such biomechanical modality is ESWT An acoustic pressure wave that penetrates tissue and produces favorable biological responses The target tissue response occurs through complex and incompletely understood Cellular and biochemical pathways.
24.
25. Shock Waves for Tissue Repair C.J. Wang JBJS 87(11): 2380-7, Nov 2005
26. A single shock wave treatment immediately after skin grafting significantly augments recipient graft revascularization. This pro-angiogenic response to ESWT is associated with significantly increased CD31 positive EC proliferation and early post treatment VEGF-A expression, upregulation of angiogenesis pathway-specific genes in the skin graft. The early pro-angiogenic and anti-inflammatory effects of ESWT in ischemic tissue make it an attractive therapeutic modality for promoting wound healing.
